VFA
NWBO

Virtus Fund Advisers’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Virtus Fund Advisers’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3,032
Closed -$20K – 2818
2014
Q2 		$20K Buy
+3,032
New +$19.3K ﹤0.01% 2457

Other funds holding NWBO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus Fund Advisers's NWBO Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2014, closing a stake of 3,032 shares — an estimated $20K sold.

Virtus Fund Advisers first reported a position in NWBO in Q2 2014 and held it in 1 quarter. The position peaked at $20K in Q2 2014. 71 funds tracked by Wall St. Rank hold NWBO as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 3,032 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2014, an estimated $20K.
  • Virtus Fund Advisers first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Northwest Biotherapeutics, Inc. Common stock position peaked at $20K in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.